{"id":108164,"date":"2009-12-28T12:01:19","date_gmt":"2009-12-28T17:01:19","guid":{"rendered":"http:\/\/www.stoth.com\/2009\/12\/28\/trigemina-takes-305k-to-treat-recurring-pain\/"},"modified":"2009-12-28T12:01:19","modified_gmt":"2009-12-28T17:01:19","slug":"trigemina-takes-305k-to-treat-recurring-pain","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/108164","title":{"rendered":"Trigemina takes $305K to treat recurring pain"},"content":{"rendered":"<p><\/p>\n<p><a title=\"Trigemina\" href=\"http:\/\/www.trigemina.com\">Trigemina<\/a>, a pharmaceutical maker working on therapies for acute and chronic pain, has brought in $305,000 of an anticipated $999,000 round of equity and rights, according to a filing with the SEC. Based in Mountain View, Calif., the company is backed by grants from the National Institutes of Health, as well as equity from private sources.<\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/J9FTLsweBlVm2R-BR6KmvdFhZOc\/0\/da\"><img decoding=\"async\" src=\"http:\/\/www.stoth.com\/wp-content\/plugins\/wp-o-matic\/cache\/762b4_di\" border=\"0\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/J9FTLsweBlVm2R-BR6KmvdFhZOc\/1\/da\"><img decoding=\"async\" src=\"http:\/\/www.stoth.com\/wp-content\/plugins\/wp-o-matic\/cache\/762b4_di\" border=\"0\"><\/img><\/a><\/p>\n<div>\n<a href=\"http:\/\/feeds.feedburner.com\/~ff\/Venturebeat?a=_e3YSijZqtM:VlNfg8_opCU:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/www.stoth.com\/wp-content\/plugins\/wp-o-matic\/cache\/762b4_Venturebeat?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Venturebeat?a=_e3YSijZqtM:VlNfg8_opCU:qj6IDK7rITs\"><img decoding=\"async\" src=\"http:\/\/www.stoth.com\/wp-content\/plugins\/wp-o-matic\/cache\/762b4_Venturebeat?d=qj6IDK7rITs\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Venturebeat?a=_e3YSijZqtM:VlNfg8_opCU:V_sGLiPBpWU\"><img decoding=\"async\" src=\"http:\/\/www.stoth.com\/wp-content\/plugins\/wp-o-matic\/cache\/762b4_Venturebeat?i=_e3YSijZqtM:VlNfg8_opCU:V_sGLiPBpWU\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Venturebeat?a=_e3YSijZqtM:VlNfg8_opCU:I9og5sOYxJI\"><img decoding=\"async\" src=\"http:\/\/www.stoth.com\/wp-content\/plugins\/wp-o-matic\/cache\/762b4_Venturebeat?d=I9og5sOYxJI\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Venturebeat?a=_e3YSijZqtM:VlNfg8_opCU:D7DqB2pKExk\"><img decoding=\"async\" src=\"http:\/\/www.stoth.com\/wp-content\/plugins\/wp-o-matic\/cache\/b412c_Venturebeat?i=_e3YSijZqtM:VlNfg8_opCU:D7DqB2pKExk\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/www.stoth.com\/wp-content\/plugins\/wp-o-matic\/cache\/b412c__e3YSijZqtM\" height=\"1\" width=\"1\" \/> <\/p>\n<p>Buy This Item: <a class=\"buy\" href=\"http:\/\/www.stoth.com\/buy.php\" ><span style=\"color: #33bc03\">[Click here to buy this item]<\/span><\/a><\/p>\n<p><a href=\"http:\/\/feedproxy.google.com\/~r\/Venturebeat\/~3\/_e3YSijZqtM\/\" >Read Original Article<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Trigemina, a pharmaceutical maker working on therapies for acute and chronic pain, has brought in $305,000 of an anticipated $999,000 round of equity and rights, according to a filing with the SEC. Based in Mountain View, Calif., the company is backed by grants from the National Institutes of Health, as well as equity from private [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-108164","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/108164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=108164"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/108164\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=108164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=108164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=108164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}